AI Image
Thyroid medicine recall receives FDA's highest risk level
USA Today • • business
Key Points:
- The FDA has upgraded a recall of Vitruvias Therapeutics Inc.'s 30 mg thyroid tablets to a Class I recall, indicating the highest risk level due to potential serious health effects or death.
- The recall affects one lot of thyroid tablets distributed nationwide from January to September 2025, with an expiration date of September 30, 2026, totaling about 3,600 units, of which approximately 1,900 were sold.
- The tablets were recalled because testing showed they could be superpotent, potentially causing overactive thyroid symptoms such as weight loss, heat intolerance, fatigue, and hypertension.
- Vitruvias Therapeutics has reported no adverse events linked to the recalled tablets as of the latest notice, and consumers are advised not to stop taking the medication without consulting their healthcare provider.
- Individuals with questions or concerns about the recall can contact Vitruvias Therapeutics directly via email or phone for further information.
